Compare RLMD & UDMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLMD | UDMY |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 784.6M | 716.5M |
| IPO Year | 2012 | 2021 |
| Metric | RLMD | UDMY |
|---|---|---|
| Price | $7.07 | $4.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $12.40 | $9.29 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.28 | ★ 105.36 |
| EPS | N/A | ★ 0.03 |
| Revenue | $13,070.00 | ★ $789,844,000.00 |
| Revenue This Year | N/A | $4.12 |
| Revenue Next Year | N/A | $4.54 |
| P/E Ratio | ★ N/A | $168.83 |
| Revenue Growth | ★ 154.83 | 0.42 |
| 52 Week Low | $0.27 | $4.18 |
| 52 Week High | $7.94 | $8.09 |
| Indicator | RLMD | UDMY |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 53.33 |
| Support Level | $3.49 | $4.30 |
| Resistance Level | $7.41 | $5.05 |
| Average True Range (ATR) | 0.44 | 0.27 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 35.01 | 64.50 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Enterprise segment and Consumer segment, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America, and also has its presence in Europe, Middle East, Africa; Asia Pacific; and Latin America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.